Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Clinical Trials01:16

Clinical Trials

10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.3K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

407
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
407

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

The American journal of cardiology·2013
Same author

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation·2013
Same author

Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Clinical cardiology·2013
Same author

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.

Circulation·2013
Same author

Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Journal of the American College of Cardiology·2013
Same author

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.

JAMA·2013

関連する実験動画

Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

P2Y12阻害剤の使用と心筋梗塞の患者における主要な心血管不良事件に対する医薬品付与券の効果:ARTEMISランダム化臨床試験

Tracy Y Wang1, Lisa A Kaltenbach1, Christopher P Cannon2

  • 1Duke Clinical Research Institute, Durham, North Carolina.

JAMA
|January 9, 2019
PubMed
まとめ
この要約は機械生成です。

P2Y12阻害剤の共同支払いの障壁を取り除くと,心筋梗塞 (MI) の患者における薬剤の持続性が増加しました. しかし,この介入は1年以内に重大な心血管疾患 (MACE) を有意に減少させなかった.

さらに関連する動画

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

関連する実験動画

Last Updated: Jan 31, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

科学分野:

  • 心血管医学
  • 臨床試験
  • 健康 経済

背景:

  • 心筋梗塞 (MI) の後,多くの患者はガイドラインに反して,早めにP2Y12阻害剤の治療を中止する.
  • 高効能のP2Y12阻害剤は十分に利用されていないため,コストが主な理由として挙げられます.
  • 薬の服用に伴う経済的障壁の影響を理解することは 心血管疾患の改善に不可欠です

研究 の 目的:

  • P2Y12阻害剤の併用費用を排除することで,患者の治療順守が改善されるかどうかを評価する.
  • 心臓発作後の患者における重大な心血管疾患 (MACE) に対する財政負担の軽減の影響を評価する.

主な方法:

  • 301の病院と11,000人以上の急性心筋梗塞の成人患者を対象としたクラスターランダム化臨床試験です.
  • 介入グループ病院は,P2Y12阻害剤 (クロピドグレルまたはチカグレル) の1年間の共同支払い券を提供しました.
  • コントロールグループは,研究で提供されたクーポンなしで通常のケアを受け,結果は退院後1年後に評価された.

主要な成果:

  • 患者によって報告されたP2Y12阻害剤の持続率は,通常の治療群 (83. 8%) と比較して,介入群で有意に高かった.
  • 改善した持続性にもかかわらず,1年後のMACE (死亡,再発性MI,または脳卒中) の複合的な結果において,統計的に有意な違いは認められなかった.
  • 介入群の患者の約72%が共同支払い券を利用した.

結論:

  • P2Y12阻害剤の共同支払い券の提供は,心臓発作後の患者の治療持続性を効果的に増加させます.
  • 経済的インセンティブだけでは,重大な心血管疾患の減少には不十分であり,他の要因がMACEに影響を及ぼすことを示唆しています.
  • 服薬費の障壁を克服することは 服薬の遵守にとって重要ですが 臨床イベントの発生率に影響を与えるには 多面的なアプローチが必要です